Literature DB >> 16965984

Just how useful an endpoint is complete pathological response after neoadjuvant chemoradiation in rectal cancer?

Rob Glynne-Jones, Nicola Anyamene.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16965984     DOI： 10.1016/j.ijrobp.2006.05.047

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN： 0360-3016            Impact factor:   7.038


× No keyword cloud information.
  11 in total

1.  A multi-centre pathologist survey on pathological processing and regression grading of colorectal cancer resection specimens treated by neoadjuvant chemoradiation.

Authors:  Runjan Chetty; Pelvender Gill; Dhirendra Govender; Adrian Bateman; Hee Jin Chang; David Driman; Fraser Duthie; Marisa Gomez; Eleanor Jaynes; Cheok Soon Lee; Michael Locketz; Claudia Mescoli; Corwyn Rowsell; Anne Rullier; Stefano Serra; Neil Shepherd; Eva Szentgyorgyi; Rajkumar Vajpeyi; Lai Mun Wang
Journal:  Virchows Arch       Date:  2012-01-13       Impact factor: 4.064

2.  The status of targeted agents in the setting of neoadjuvant radiation therapy in locally advanced rectal cancers.

Authors:  Rob Glynne-Jones; Maher Hadaki; Mark Harrison
Journal:  J Gastrointest Oncol       Date:  2013-09

3.  Human cytomegalovirus and Epstein-Barr virus infection impact on (18)F-FDG PET/CT SUVmax, CT volumetric and KRAS-based parameters of patients with locally advanced rectal cancer treated with neoadjuvant therapy.

Authors:  Claudio V Sole; Felipe A Calvo; Carlos Ferrer; Emilio Alvarez; Jose L Carreras; Enrique Ochoa
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-10-01       Impact factor: 9.236

4.  Reply to the letter "How to standardize the evaluation of tumor regression grading of gastrointestinal cancers after neoadjuvant therapy?" by Dr. Nasierowska-Guttmejer and Dr. Szawlowski, VIAR-D-18-00181.

Authors:  Rupert Langer; Karen Becker
Journal:  Virchows Arch       Date:  2018-06-21       Impact factor: 4.064

5.  Clinical significance of VEGFR-2 and ¹⁸F-FDG PET/CT SUVmax pretreatment score in predicting the long-term outcome of patients with locally advanced rectal cancer treated with neoadjuvant therapy.

Authors:  Claudio V Sole; Felipe A Calvo; Emilio Alvarez; Isabel Peligros; Pilar Garcia-Alfonso; Carlos Ferrer; Enrique Ochoa; Rafael Herranz; Jose L Carreras
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-06-26       Impact factor: 9.236

6.  Quantitative imaging outperforms molecular markers when predicting response to chemoradiotherapy for rectal cancer.

Authors:  Ines Joye; Annelies Debucquoy; Christophe M Deroose; Vincent Vandecaveye; Eric Van Cutsem; Albert Wolthuis; André D'Hoore; Xavier Sagaert; Mu Zhou; Olivier Gevaert; Karin Haustermans
Journal:  Radiother Oncol       Date:  2017-06-21       Impact factor: 6.280

Review 7.  Adjuvant and neoadjuvant chemoradiation or radiotherapy in rectal cancer--a review focusing on open questions.

Authors:  Lutz Moser; Jörg-Peter Ritz; Wolfgang Hinkelbein; Stefan Höcht
Journal:  Int J Colorectal Dis       Date:  2007-12-07       Impact factor: 2.571

8.  Colorectal Cancer Association of Canada consensus meeting: raising the standards of care for early-stage rectal cancer.

Authors: 
Journal:  Curr Oncol       Date:  2009-12       Impact factor: 3.677

Review 9.  Optimal Time Intervals between Pre-Operative Radiotherapy or Chemoradiotherapy and Surgery in Rectal Cancer?

Authors:  Bengt Glimelius
Journal:  Front Oncol       Date:  2014-04-07       Impact factor: 6.244

10.  Prognostic value of mandard and dworak tumor regression grading in rectal cancer: study of a single tertiary center.

Authors:  Marisa D Santos; Cristina Silva; Anabela Rocha; Eduarda Matos; Carlos Nogueira; Carlos Lopes
Journal:  ISRN Surg       Date:  2014-03-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.